Arecor

Cambridge, United Kingdom Founded: 2007 • Age: 19 yrs
Developer of proteins, vaccines based on proprietary stabilization technologies for drug delivery
Request Access

About Arecor

Arecor is a company based in Cambridge (United Kingdom) founded in 2007.. Arecor has raised $16.27 million across 5 funding rounds from investors including Gov.uk, Downing and Calculus Capital. Arecor has completed 1 acquisition, including Tetris Pharma. Arecor offers products and services including Arestat Technology and Enhanced Medicines. Arecor operates in a competitive market with competitors including Ensysce, Oxular, EryDel, PharmaJet and Splice Bio, among others.

  • Headquarter Cambridge, United Kingdom
  • Stage Public
  • Sectors
    Healthcare
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Arecor Therapeutics Plc
Operational Areas
Healthcare → Pharmaceuticals & Therapeutics
Key Metrics
  • Annual Revenue
    $6.33 M (USD)
    10.5
    as on Dec 31, 2024
  • Net Profit
    $-12.83 M (USD)
    -19.66
    as on Dec 31, 2024
  • EBITDA
    $-8.83 M (USD)
    27.18
    as on Dec 31, 2024
  • Total Equity Funding
    $16.27 M (USD)

    in 5 rounds

  • Latest Funding Round
    $8.26 M (USD), Series B

    Jul 24, 2024

  • Investors
    Gov.uk

    & 4 more

  • Employee Count
    Employee Count
  • Investments & Acquisitions
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

IPO & Listings of Arecor

Arecor is a publicly listed company on the LSE with ticker symbol AREC in UK, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

Exchange: LSE · Ticker: AREC . Sector: Health technology · UK

Products & Services of Arecor

Arecor offers a comprehensive portfolio of products and services, including Arestat Technology and Enhanced Medicines. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Platform for developing enhanced medicines for diabetes treatments.

Medicines targeting diabetes and obesity management through partnerships.

People of Arecor
Headcount 10-50
Employee Profiles 11
Board Members and Advisors 8
Employee Profiles
People
Sheena Singadia
Formulation Lead
People
Ilaria Passarini
Formulation Lead
People
Andrea Tenslin
Scientist
People
Katerina-Asteria Rousou
Scientist II

Unlock access to complete

Board Members and Advisors
people
Bruce Buckingham
Scientific Advisor
people
Christine Soden
Non-Executive Director
people
Thomas R. Pieber
Scientific Advisor
people
Sam Fazeli
Non-Executive Director

Unlock access to complete

Funding Insights of Arecor

Arecor has successfully raised a total of $16.27M across 5 strategic funding rounds. The most recent funding activity was a Series B round of $8.26 million completed in July 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding
  • Total Rounds 5
  • Last Round Series B — $8.3M
  • First Round

    (01 Jan 2008)

  • Investors Count 5
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2024 Amount Series B - Arecor Valuation

investors

Mar, 2021 Amount Grant - Arecor Valuation

investors

Sep, 2018 Amount Series A - Arecor Valuation Albion Capital Group , Calculus Capital
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Arecor

Arecor has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include Gov.uk, Downing and Calculus Capital. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Venture Fund
Institutional
Investor Description Founded Year Domain Location
Venture capital investments are managed by Albion Capital.
Founded Year Domain Location
UK venture capital investments are managed by Calculus Capital.
Founded Year Domain Location
Inheritance tax relief, funds, and bonds are provided across sectors.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Arecor

Arecor has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Tetris Pharma. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Acquisitions
Company Name Description Domain Location Founded Year Amount
Marketing services for healthcare products are provided by Tetris Pharma.
2020
Company Name Description Domain Location Founded Year Amount
OVO is recognized as a smart digital payment application.
2017
Bionic investment advisor platform
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014

Financial Statements - Arecor

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Arecor Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Arecor

Arecor operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Ensysce, Oxular, EryDel, PharmaJet and Splice Bio, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Drug delivery solutions via single-walled carbon nanotubes are offered.
domain founded_year HQ Location
Drug delivery platforms and therapeutics for ophthalmology are developed.
domain founded_year HQ Location
Erythrocyte encapsulation systems for drug delivery are developed.
domain founded_year HQ Location
Provider of needle-free injection technology
domain founded_year HQ Location
Provider of a proprietary platform for gene therapy
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Arecor

Frequently Asked Questions about Arecor

When was Arecor founded?

Arecor was founded in 2007 and raised its 1st funding round 1 year after it was founded.

Where is Arecor located?

Arecor is headquartered in Cambridge, United Kingdom. It is registered at Cambridge, Cambridgeshire, United Kingdom.

Is Arecor a funded company?

Arecor is a funded company, having raised a total of $16.27M across 5 funding rounds to date. The company's 1st funding round was a Series A of $7.75M, raised on Jan 01, 2008.

What is the annual revenue of Arecor?

Annual revenue of Arecor is $6.33M as on Dec 31, 2024.

What does Arecor do?

Arecor was founded in 2007 in Cambridge, United Kingdom, within the biotechnology sector. Stabilization technologies are utilized to formulate proteins and vaccines as stable aqueous or dry preparations, suitable for high concentrations or ionizing radiation exposure. The Arestat platform is integrated into existing manufacturing processes without covalent modifications to biologics, employing only GRAS excipients approved by regulatory authorities. Operations focus on enhancing drug delivery formulations.

Who are the top competitors of Arecor?

Arecor's top competitors include Oxular, PharmaJet and Splice Bio.

What products or services does Arecor offer?

Arecor offers Arestat Technology and Enhanced Medicines.

Is Arecor publicly traded?

Yes, Arecor is publicly traded on LSE under the ticker symbol AREC.

How many acquisitions has Arecor made?

Arecor has made 1 acquisition, including Tetris Pharma.

Who are Arecor's investors?

Arecor has 5 investors. Key investors include Gov.uk, Downing, Calculus Capital, Albion Capital, and Seneca Growth Capital.

What is Arecor's ticker symbol?

The ticker symbol of Arecor is AREC on LSE.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available